Cambridge stem cell firm raises £1.5m for safer drug trials – Cambridge News
|
Cambridge stem cell firm raises £1.5m for safer drug trials
Cambridge News DefiniGEN, a leading provider of stem cell life science products, has raised £1.5m in follow-on funding. The round was led by Cambridge Enterprise, the commercialization arm of the university, and 24 Haymarket, with key investors Dr Jonathan Milner … |
